Taivex Therapeutics Corp. (Taivex) and The National Health Research Institutes (NHRI) are pleased to announce the technology transfer of T-1301 (formerly, DBPR216), a potential anti-cancer developmental drug candidate, effective on April 8.

T-1301 is a novel small molecular multi-target tyrosine kinase inhibitor (TKI), which is orally available and exhibited potent inhibitory efficacy against both wild type and mutant forms of multiple oncogenic kinases, and shows its potential of multiple cancer indications.

In in vitro studies, T-1301 effectively inhibits tumor cell growth of acute myeloid leukemia (AML), as well as gastrointestinal stromal tumor (GIST) carrying mutations resulting in drug resistances to commercial anti-cancer therapies, i.e., Glivec/Gleevec, Sutent and Stivarga. In in vivo animal studies, T-1301 exhibited effective growth inhibitions against various types of human cancers, including hematological malignancies (e.g., AML) and various types of solid tumors, including GIST, colorectal cancer, gastric cancer, lung cancer, nasopharyngeal cancer, oral cancer, ovarian cancer, breast cancer, and MDR1-driven chemorefractory tumors.

Taivex will carry out the preclinical and clinical development of T-1301 and advance its commercialization.